ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether CytoDyn Inc. (“CytoDyn” or the “Company”) (OTC: CYDY) complied with federal securities laws. On April 27, 2020, CytoDyn issued a press release indicating it had submitted a “completed Biologics License Application (BLA) to the FDA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients.” On May 7, 2020, CytoDyn announced that its BLA for Leronlimab “will be considered completed after the clinical datasets are submitted on May 11, 2020.”
If you purchased shares of CytoDyn and suffered a loss on that investment, you are encouraged to contact Marshall P. Dees, Esq. at firstname.lastname@example.org or Luke R. Kennedy at email@example.com, or at www.holzerlaw.com to discuss your legal rights.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.